References
- Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 2021; 18: 298-307. doi: 10.20892/j.issn.2095-3941.2020.0559
- Venkatesulu BP, Chandrasekar VT, Girdhar P, Advani P, Sharma A, Elumalai T, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr 2021; 5: pkaa102. doi: 10.1093/jncics/pkaa102
- Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e2210880. doi: 10.1001/jamanetworkopen.2022.10880
- Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol 2020; 6: 799-808. doi: 10.1200/GO.20.00225
- Tang K, Wei Z, Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol 2022; 94: 4860-8. doi: 10.1002/jmv.27956
- Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutierrez T, Tagliamento M, et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 2022; 160: 243-60. doi: 10.1016/j.ejca.2021.10.014
- Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol 2022; 15: 15. doi: 10.1186/s13045-022-01233-3
- Shields AM, Venkatachalam S, Shafeek S, Paneesha S, Ford M, Sheeran T, et al. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study. Clin Exp Immunol 2022; 207: 3-10. doi: 10.1093/cei/uxab018
- Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv 2021; 5: 3053-61. doi: 10.1182/bloodadvances.2021005094
- Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 2021; 5: 2624-43. doi: 10.1182/bloodadvances.2021004629
- Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer 2022; 3: 552-64. doi: 10.1038/s43018-022-00364-3 Moor
- Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine 2022; 40: 1203-7. doi: 10.1016/j.vaccine.2022.01.040
- Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, et al. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheumatol 2022; 74: 934-47. doi: 10.1002/art.42060
- Asplund Hogelin K, Ruffin N, Pin E, Hober S, Nilsson P, Starvaggi Cucuzza C, et al. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Eur J Neurol 2022; 29: 3317-28. doi: 10.1111/ene.15492
- Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA Oncol 2022; 8: 1477-83. doi: 10.1001/jamaoncol.2022.3227
- Avivi I, Luttwak E, Saiag E, Halperin T, Haberman S, Sarig A, et al. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses. Br J Haematol 2022; 196: 1329-33. doi: 10.1111/bjh.18029
- Pinder CL, Jankovic D, Fox TA, Kirkwood A, Enfield L, Alrubayyi A, et al. Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination. Br J Haematol 2023; 202: 1091-103. doi: 10.1111/bjh.18962
- Schubert L, Koblischke M, Schneider L, Porpaczy E, Winkler F, Jaeger U, et al. Immunogenicity of COVID-19 vaccinations in hematological patients: 6-month follow-up and evaluation of a 3rd vaccination. Cancers (Basel) 2022; 14: 1962. doi: 10.3390/cancers14081962
- Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139-45. doi: 10.1016/j.clim.2006.08.009
- Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 2011; 29: 5-9. doi: 10.1002/hon.947 Lim
- Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, Moller B, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 2021; 3: e789-97. doi: 10.1016/S2665-9913(21)00251-4
- Fattizzo B, Rampi N, Barcellini W. Vaccinations in hematological patients in the era of target therapies: lesson learnt from SARS-CoV-2. Blood Rev 2023; 60: 101077. doi: 10.1016/j.blre.2023.101077
- Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P, et al. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica 2022; 107: 715-20. doi: 10.3324/haematol.2021.279216
- Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, et al. Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti-SARS-CoV-2 vaccination in mature B-cell neoplasms. Infect Drug Resist 2023; 16: 509-19. doi: 10.2147/IDR.S396271
- Shree T, Shankar V, Lohmeyer JJK, Czerwinski DK, Schroers-Martin JG, Rodriguez GM, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov 2022; 3: 95-102. doi: 10.1158/2643-3230.BCD-21-0222
- Tsutsumi Y, Ito S, Horikita F, Moriki A, Teshima T. COVID-19 antibody production by vaccination in chemotherapy with CD20 antibody for B-cell lymphoma. Mol Clin Oncol 2023; 19: 96. doi: 10.3892/mco.2023.2692
- Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, et al. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximabtreated patients: an open-label extension study. Ann Rheum Dis 2022; 81: 1750-6. doi: 10.1136/ard-2022-222579
- Debie Y, van Dam PA, Goossens ME, Peeters M, Vandamme T. Boosting capacity of a fourth dose BNT162b2 in cancer patients. Eur J Cancer 2023; 179: 121-3. doi: 10.1016/j.ejca.2022.11.016
- Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, et al. Rituximabtreated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol 2022; 197: 697-708. doi: 0.1111/bjh.18149
- Komlodi-Pasztor E, Escarra-Senmarti M, Bazer DA, Bhatnagar A, Perez Heydrich CA, Messmer M, et al. The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment. Front Immunol 2024; 15: 1433442. doi: 10.3389/fimmu.2024.1433442
- Gressens SB, Wiedemann A, Dechenaud M, Dupuis J, Gallien S, Melica G, et al. Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 2023; 41: 1550-3. doi: 10.1016/j.vaccine.2023.01.064